Solstice Biologics is a private company focused on solving
the problem of targeting and delivery of nucleic acid therapeutics.
The company is developing small, cell-permeable RNAi pro-drugs that
can enter many different cell types and deliver on the promise of
RNAi therapeutics. In January 2013, Solstice raised $18 million in
a Series A financing backed by venBio and Aeris